Epigenetic modifier-induced biosynthesis of novel fusaric acid derivatives in endophytic fungi from Datura stramonium L. by Han-Jing Chen et al.
Regular Article                                                                                                                                     Nat. Prod. Bioprospect. 2013, 3, 20–23 
DOI 10.1007/s13659-013-0010-2 
 
         
Epigenetic modifier-induced biosynthesis of novel fusaric acid derivatives
in endophytic fungi from Datura stramonium L. 
Han-Jing CHEN, Takayoshi AWAKAWA, Jie-Yin SUN, Toshiyuki WAKIMOTO, and Ikuro ABE* 
Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan 
 
Received 2 February 2013; Accepted 16 February 2013 
© The Author(s) 2013. This article is published with open access at Springerlink.com 
 
Abstract: The treatment of fungi with DNA methyltransferase (DNMT) and/or histone deacetylase (HDAC) inhibitors is a  
promising way to activate secondary metabolite biosynthetic pathways that are dormant under normal conditions. In this study, we 
included an HDAC inhibitor, suberoylanilide hydroxamic acid (SBHA), in the culture medium of endophytic fungi isolated from 
the medicinal plant Datura stramonium L. The production of two compounds was induced in the culture supplemented with SBHA, 
and their structures were determined to be the fusaric acid derivatives 5-butyl-6-oxo-1,6-dihydropyridine-2-carboxylic acid and  
5-(but-9-enyl)-6-oxo-1,6-dihydropyridine-2-carboxylic acid. The result confirmed that the use of chemical epigenetic modifiers is 
an effective technique for promoting the expression of silent biosynthetic pathways to produce unique secondary metabolites. 
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Introduction 
Fungi are talented organisms capable of producing 
pharmaceutically useful compounds, as exemplified by 
penicillin, cyclosporine and lovastatin.1 The sequences of 
fungal genomes revealed the presence of many more genes 
encoding enzymes that produce secondary metabolites, as 
compared to those producing the known chemicals isolated 
from fungi. This suggested that many genes responsible for the 
production of secondary metabolites are not expressed in the 
artificial environment of the laboratory. Thus, the expression 
of such dormant genes in fungi is a promising way to obtain 
novel bioactive compounds. Recent studies revealed that 
histone deacetylase (HDAC) and DNA methyltransferase 
(DNMT) inhibitors are useful for activating dormant 
biosynthetic genes.2–5 Indeed, the manipulation of the HDAC 
and DNMT activities by chemical agents alters the gene 
expression patterns in fungi, resulting in the production of 
novel secondary metabolites.2–5 
Endophytic fungi from plants produce numerous biologically
active compounds.6 These also include compounds reported as 
originating from plants, such as taxol and camptothecin. These 
reports suggested that gene transfer events may occur between 
endophytic fungi and plants. Thus, investigations of secondary 
metabolite biosynthesis in endophytic fungi will broaden our 
comprehension of plant metabolite biosynthesis. Datura  
stramonium L. produces pharmaceutically important tropane 
alkaloids, such as scopolamine and hyoscyamine, via largely 
unknown biosynthetic pathways. To obtain clues about  
tropane alkaloid biosynthesis, we isolated several endophytic 
fungi from D. stramonium L, expecting to obtain fungal  
producers of tropane alkaloids.7 Contrary to our expectations, 
none of the strains produced tropane alkaloids under the  
various conditions we tested. During this process, one strain 
isolated from the stem of D. stramonium L. produced several 
mycotoxins, such as alternariol, tenuazonic acid, and altertoxin 
II, in the presence of 5-azacytidine (a DNMT inhibitor) or 
suberoylanilide hydroxamic acid (SBHA, an HDAC inhibitor).7
Likewise, another species was isolated from the root of D. 
stramonium L., which we named R1 and identified as Fusarium
oxysporum f. sp. conglutinans strain MAFF744001, based on 
the sequence of its rRNA ITS region.8 Since endophytic fungi 
are known as prolific sources of pharmacologically active 
compounds, we searched for the metabolites produced by R1. 
To fully exploit its biogenetic capability, we incubated the R1 
strain in the presence of epigenetic modifiers, and monitored 
its products. Our approach led to the isolation of 5-butyl-6-
oxo-1,6-dihydropyridine-2-carboxylic acid (1) and 5-(but-9-
enyl)-6-oxo-1,6-dihydropyridine-2-carboxylic acid (2), which 
are derivatives of fusaric acid (Figure 1). 1 and 2 are novel 
compounds isolated from nature. 
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Figure 1.  Structures of compounds 1 and 2 
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Results and Discussion 
The R1 strain was incubated in 75 mL of liquid medium in 
the presence and absence of 500 µM SBHA. The ethyl acetate 
extract of the culture filtrate was subjected to HPLC equipped 
with an ODS column. As a result, the production of the two 
new products 1 and 2, which had not been detected under 
normal conditions, was induced by SBHA (Figure 2). In 
contrast, fusaric acid, which was identified by comparisons of 
its 1H and 13C NMR spectra with the published spectra (see 
Experimental Section), was detected in the cultures even in the 
absence of SBHA.  
To identify the structures of 1 and 2, the ethyl acetate 
extract from a large-scale culture (6 × 75 mL) was separated 
by reverse-phase HPLC. The molecular formula of 1 was 
established as C10H13NO3 by positive ion ESITOFMS, 
suggesting that the degree of unsaturation was five. The 1H 
NMR spectrum (DMSO-d6) of 1 exhibited signals for two 
aromatic methine protons (H = 6.81 and 7.31), three 
methylene protons (H = 1.24, 1.43 and 2.39) and one methyl 
proton (H = 0.84) (Table 1). The COSY analysis revealed that 
these aliphatic protons (H = 1.24, 1.43 and 2.39) and one 
methyl proton (H = 0.84) were in the same spin system, 
indicating that 1 contains an n-butyl group (Figure 3). The 
HMQC and HMBC analyses of 1 [H = 2.39 (2H, t, J = 7.5 
Hz); C = 138.2 and 163.1] confirmed the connection between 
the n-butyl group and the aromatic ring (Figure 3). In addition 
to these data, there were two quaternary carbons (C = 162.2 
and 163.1) in the 13C NMR spectrum of 1 (Table 2).  Their 
chemical shifts were consistent with two carbonyl groups, and 
each must be a carboxyl and an amide carbonyl to satisfy the 
molecular formula. Thus, the structure of 1, containing an 
alkyl group, aromatic ring, amide group and carboxyl group, 
was reminiscent of fusaric acid. In fact, the 1H and 13C NMR 
spectra of 1 were similar to those of fusaric acid, but lacked 
one of the three aromatic protons present in its 1H NMR 
spectrum [H = 8.54 (1H, s)] (Tables 1 and 2), implying that 1 
is a fusaric acid derivative with an oxygenated aromatic ring. 
The spin system of the aromatic protons of 1 suggested that a 
carbon atom (C-6) adjacent to a nitrogen atom in fusaric acid 
was oxygenated. Therefore, the structure of 1 was deduced to 
be 6-hydroxyl fusaric acid, which raised the question of 
whether 1 is stable as the pyridone or hydroxypyridine. 
Considering the fact that 1 was negative against the FeCl3 
reaction for the detection of phenols on TLC, the keto form of 
1 might be the predominant tautomer. Therefore, we 
concluded that 1 is 5-butyl-6-oxo-1,6-dihydropyridine-2-
carboxylic acid (Figure 1). 
The 1H NMR spectra of 2 were quite similar to those of 1, 
except for three proton signals (H = 4.92, 4.99 and 5.77) 
(Table 1). The COSY analysis revealed that these protons (H 
= 4.92, 4.99 and 5.77) and the aliphatic protons (H = 2.25, and 
2.46) were in the same spin system, indicating that 2 contains 
a 9,10-dehydrobutyl group in place of the n-butyl group of 1 
(Figure 3). In a similar manner as for 1, the HMQC and 
HMBC analyses of 2 [H = 2.46 (2H, m); C = 137.7 and 162.6] 
confirmed the connection between the 9,10-dehydrobutyl 
group and the aromatic ring. Therefore, 2 was assumed to be 
the dehydro form of 1. The methyl ester of 2 generated an ion 
peak corresponding to the [M + H]+ at m/z 208.0956 (calcd for 
C11H14NO3 208.0968) in ESITOFMS. These data revealed that 
the structure of 2 is 5-(but-9-enyl)-6-oxo-1,6-dihydropyridine-
2-carboxylic acid (Figure 1). 
The antibacterial activities of 1 and 2 were tested with 
Bacillus cereus. Compounds 1 and 2 were dissolved in MeOH 
and serially diluted to final sample concentrations from 400–0 
 
Figure 2.  HPLC analyses of the culture supernatant of R1 
strain: (i) a culture incubated in PD broth, (ii) a culture 
incubated in PD broth containing SBHA. Elutions were 
monitored by UV absorption at 220 nm. 
Table 2. 13C NMR spectroscopic data of compound 1 and 2 in 
DMSO-d6 
no. 1a 2a no. 1a 2a 
2 134.9 C 135.7 C 8 30.3 CH2 32.5 
3 109.3 CH 110.3 CH 9 22.5 CH2 138.8 CH 
4 136.6 CH 137.7 CH 10 14.3 CH3 
5 138.2 C 139.0 C 10a  116.1 CH2
6 163.1 C 162.6 C 10b  116.1 CH2
7 30.2 CH2 30.5 CH2 11 162.2 C 162.4 C 
aMeasured at 125 MHz 
Table 1. 1H NMR spectroscopic data of compound 1 and 2 in 
DMSO-d6 
no. 1a 2a 
3 6.81 (1H, d, 7.0) 6.84 (1H, d, 7.0) 
4 7.31 (1H, d, 7.0) 7.34 (1H, d, 7.0) 
5  
6  
7 2.39 (2H, t, 7.5) 2.46 (2H, m) 
8 1.43 (2H, m) 2.25 (2H, m) 
9 1.24 (2H, m) 5.77 (1H, m) 
10 0.84 (3H, t, 7.5)  
10a 4.99 (1H, dd, 18.0, 1.75)
10b  4.92 (1H, dd, 10.3, 1.75)
aMeasured at 500 MHz 
 
Figure 3.  COSY and HMBC correlations of 1 and 2 
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µg/mL. While fusaric acid exhibited antibacterial activity 
(MIC = 25 µg/mL), neither 1 nor 2 showed any activity, 
indicating that the oxidation of the pyridine ring significantly 
diminished the antibacterial activity of fusaric acid. This fact 
implied that these compounds would not kill bacteria within or 
on the plant, and thus not confer any advantage for the 
survival of its producer. Since fusaric acid is toxic to plant 
physiological processes as well as to microorganisms,9 it might 
be oxidized into 1 and 2 for the sake of alleviating the toxicity 
to the plant. This led us to assume that the biosynthetic routes 
for the production of 1 and 2 from fusaric acid could be 
specific for endophytic Fusarium species. In fact, F. 
oxysporum FGSC9935, which is not an endophytic strain, 
could not produce 1 and 2 even in the presence of SBHA (data 
not shown). Alternatively, compounds 1 and 2 are biosynthetic 
precursors of fusaric acid. A reduction step followed by a 
dehydration step would convert 1 into fusaric acid. 
By supplying SBHA to the culture, 5-butyl-6-oxo-1,6-
dihydropyridine-2-carboxylic acid (1) and 5-(but-9-enyl)-6-
oxo-1,6-dihydropyridine-2-carboxylic acid (2) were isolated 
from the endophyte strain belonging to F. oxysporum. Even 
though fusaric acid was previously isolated from F.  
oxysporum10 and F. verticillioides11, both 1 and 2 were novel 
compounds isolated from natural sources. The synthesis of 1 
was outlined in a US patent reported in 1975, in which a 
chemical library of 5-alkylpyridine-2-carboxylates was  
constructed to obtain compounds with dopamine--
hydroxylase activity.12 In this patent, neither the NMR spectra 
nor the dopamine--hydroxylase activity of 1 were described. 
Therefore, this is the first report of the spectral data of 1. On 
the other hand, compound 2 has not been synthesized or  
isolated so far. Hence, this novel compound was not detected 
until an epigenetic modifier was used to treat the fungal  
culture. This report demonstrates that the use of epigenetic 




General Experimental Procedures. D. stramonium L. was 
a kind gift from Dr. Noguchi, of the University of Shizuoka. 
SBHA was purchased from Sigma. PD broth was purchased 
from Difco. Oligonucleotide primers were purchased from 
Operon Biotechnologies (Tokyo). 
 
Isolation and Identification of Endophytic Fungi. The 
isolation of endophytic fungi from D. stramonium L. was  
performed as described previously.7 The R1 strain was identi-
fied by a DNA fragment of the fungal rDNA ITS region.8 The  
genomic DNA of R1 was extracted. PCR was performed with 
the primers ITR1 (5’-TCCGTAGGTGAACCTGCGG-3’) and 
ITS4 (5’-TCCTCCGCTTATTGATATGC-3’) and DNA  
isolated from R1 by phenol/chloroform/isoamyl alcohol = 
25:24:1 extraction, using KAPATaq Extra DNA polymerase 
(KAPA Biosystems) and the following program: 94 ºC, 2 min; 
(94 ºC, 15 s; 55 ºC, 15 s; 72 ºC, 60 s)  35 cycles. The  
amplified fragment was sequenced on an Applied Biosystems 
3130XL sequencer. 
 
HPLC Analysis of the Compound Accumulated in the 
Broth of R1. The mycelia of R1 were grown on PD agar 
medium at 30 ºC for 7 days and then inoculated into 75 mL of 
liquid PD medium containing 500 µM SBHA in a 500 mL 
flask, incubated at 28 ºC under static conditions for 7 days. 
The broth culture filtrate was collected and successively 
extracted with ethyl acetate. The organic layer was 
concentrated and subjected to HPLC analysis. The extract was 
analyzed by HPLC equipped with a TSKgel ODS-80Ts QA 
column (TOSO), with a solvent system of water containing 
0.1% TFA (solvent A) and methanol containing 0.1% TFA 
(solvent B), at a flow rate of 0.8 mL/min and a column 
temperature of 40 ºC. Separation was performed with a linear 
gradient from solvent B/solvent A (10:90) to 100:0 within the 
following 30 min, 100:0 for an additional 15 min and a linear 
gradient from 100:0 to 10:90 within the following 5 min. 
 
Characterization of 1 and 2. The R1 strain was inoculated 
into six 500 mL flasks, each with 75 mL of liquid PD medium 
containing 500 µM SBHA, and incubated at 28 ºC for 7 days. 
The broth culture filtrate was collected, successively extracted 
with ethyl acetate and then dried, for detection by HPLC. For 
structural identification, the crude extract was separated by 
HPLC equipped with a COSMOSIL 5C18-AR-II column 
(Nacalai Tesque), using a solvent system of water containing 
0.1% TFA (solvent A) and methanol containing 0.1% TFA 
(solvent B), at a flow rate of 2.5 mL/min and a column 
temperature of 40 ºC. The gradient program was the same as 
described above. As a result, 5.28 mg of 1, 1.23 mg of 2 and 
4.32 mg of fusaric acid were prepared. The 1H and 13C NMR 
spectra were recorded on a JEOL ECX-500 spectrometer in 
DMSO-d6. The NMR data of 1 and 2 are summarized in  
Tables 1 and 2, and the NMR data of fusaric acid are  
summarized below. 1 was subjected to an ESITOFMS 
(BRUKER DALTONICS) analysis, and the [M + H]+ ion peak 
at m/z 196.0989 [M + H]+ (calcd for C10H14NO3, 196.0968) 
was detected. 
 
Preparation of Methyl Ester of 2. To the MeOH solution 
(0.1 mL) of 2 (0.1 mg) was added 600 µL of a diethyl ether 
solution of diazomethane. The mixture was allowed to slowly 
warm to room temperature. After 6 hours, the sample was 
subjected to the ESITOFMS analysis, and the [M + H]+ ion 
peak at m/z 208.0956 (calcd for C11H14NO3 208.0968) was 
detected. 
 
Antibacterial Activity Assay. The antibacterial activity of 
the test compounds was assessed using Bacillus cereus, which 
was grown in LB medium at 37 ºC for 12 hours. The assays 
were conducted in 96-well microtiter plates. A 10 µL portion 
of the LB medium culture of B. cereus was suspended in 10 
mL Mueller Hinton broth, and an appropriate volume was 
added to each row. The test compounds were dissolved in 
MeOH, and 2 µL aliquots were added to the first row. Serial 
dilutions were prepared to make final sample concentrations of 
400, 200, 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, and 0 
µg/mL, and 2 µL aliquots were added to the following rows. 
After an incubation at 37 ºC for 16 hours, the MIC values were 
determined visually. 
 
5-Butyl-6-oxo-1,6-dihydropyridine-2-carboxylic acid (1): 
white solid; UV (MeOH) max 247, 311 nm; 1H NMR (DMSO-
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d6, 500 MHz) and 13C NMR (DMSO-d6, 125 MHz) data, see 
Tables 1 and 2; ESIMS (positive) m/z 196 [M + H]+; 
HRESIMS m/z 196.0989 (calcd for C10H14NO3, 196.0968). 
 
5-(But-9-enyl)-6-oxo-1,6-dihydropyridine-2-carboxylic 
acid (2): white solid; UVmax (MeOH) max 247, 311 nm; 1H 
NMR (DMSO-d6, 500 MHz) and 13C NMR (DMSO-d6, 125 
MHz) data, see Tables 1 and 2; ESIMS (positive, methylated 2) 
m/z 196 [M + H]+; HRESIMS m/z 208.0956 (calcd for 
C11H14NO3 208.0968). 
 
Fusaric acid: white solid; UVmax (MeOH) max 224, 269 nm. 
1H NMR (DMSO-d6, 500 MHz):  0.92 (3H, m, H-10), 1.32 
(2H, m, J = 1.7 Hz, H-9), 1.58 (2H, m, J = 2.3 Hz, H-8), 2.66 
(2H, t, J = 8.0 Hz, H-7), 7.85 (1H, d, J = 8.0 Hz, H-4), 8.00 
(1H, d, J = 8.0 Hz, H-3), 8.54 (1H, s, H-6). 13C NMR (DMSO-
d6, 125 MHz):  14.3 (CH3, C-10), 22.3 (CH2, C-9), 32.3 (CH2, 
C-7), 33.1 (CH2, C-8), 125.2 (CH, C-3), 137.7 (CH, C-4), 
142.5 (C, C-5), 146.2 (C, C-2), 149.7 (CH, C-6), 166.5 (C, C-
11). ESIMS (positive) m/z 180 [M + H]+; HRESIMS m/z 
180.1030 [M + H]+ (calcd for C10H14NO2, 180.1019). 
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